Skip to main content
BioAge Labs, Inc. logo

BioAge Labs, Inc. — Investor Relations & Filings

Ticker · BIOA ISIN · US09077V1008 LEI · 529900NG0C40250Z7875 US Manufacturing
Open in API
Filings indexed 129 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country US United States of America
Listing US BIOA

About BioAge Labs, Inc.

https://bioagelabs.com

BioAge Labs, Inc. is a clinical-stage biotechnology company that develops therapies for metabolic diseases by targeting the molecular mechanisms of human aging. The company's mission is to extend healthy lifespan. It utilizes a proprietary, human-first discovery platform that analyzes multi-omics data from longitudinal biobanks to identify novel targets that drive aging and disease. BioAge's therapeutic pipeline focuses on cardiometabolic conditions such as obesity and cardiovascular disease. Key programs include BGE-102, an NLRP3 inhibitor designed to block chronic inflammation, and an apelin receptor (APJ) agonist that functions as an exercise mimetic to improve body composition and enhance weight loss.

Recent filings

Filing Released Lang Actions
8-K - BioAge Labs, Inc. (0001709941) (Filer)
Regulatory Filings Classification · 87% confidence The document is a United States SEC Form 8-K “Current Report” filing under Section 13 or 15(d), notifying the SEC of a press release (Exhibit 99.1) reporting first quarter financial results. It does not itself contain the full earnings data, but serves as a regulatory notification. There is no dedicated category for 8-K filings, so under the fallback rules this is classified as a generic regulatory filing.
2026-05-08 English
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
S-3ASR - BioAge Labs, Inc. (0001709941) (Filer)
Regulatory Filings
2026-03-24 English
S-8 - BioAge Labs, Inc. (0001709941) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement, which is a filing used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. The text includes detailed tables calculating the registration fee for newly registered securities, referencing the Securities Act of 1933 and specific rules for fee calculation. There is no indication that this is an announcement or summary; rather, it is the actual registration statement filing. This type of document is related to capital raising and securities registration under employee plans, which fits the Capital/Financing Update category (CAP).
2026-03-24 English
10-K - BioAge Labs, Inc. (0001709941) (Filer)
Annual Report FY 2025
2026-03-24 English
8-K - BioAge Labs, Inc. (0001709941) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text indicates that the company issued a press release announcing its financial results for the year ended December 31, 2025, and attached the press release as an exhibit. The document itself does not contain detailed financial statements or comprehensive analysis but rather points to the press release and an updated corporate deck on the website. The length of the document is 3870 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or attaches a report but does not contain the full report itself should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-24 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.